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Abstract
Background: Basal-like breast cancer has been extensively characterized on the basis of gene
expression profiles, but it is becoming increasingly common for these tumors to be defined on the
basis of immunohistochemical (IHC) staining patterns, particularly in retrospective studies where
material for expression profiling may not be available. The IHC pattern that best defines basal-like
tumors is under investigation and various combinations of ER, PR, HER2-, CK5/6+ and EGFR+ have
been tested.
Methods: Using datasets from two different hospitals we describe how using different
combinations of immunohistochemical patterns has different effects on estimating prognosis at
different time intervals after diagnosis. As our baseline, we used two IHC patterns ER-/PR-/HER2-
("triple negative phenotype", TNP) and ER-/HER2-/CK5/6+ and/or EGFR+ ("core basal phenotype",
CBP).
Results: There was no overall difference in survival between the two hospital-based series, but
there was a difference between the TNP and non-TNP groups which was most marked at 3 years
(76.8% vs 93.5%, p < .0001). This difference reduced with time, suggesting that long term survivors
(beyond 10 years) in the TNP group may have comparable survival to non-TNP cases. A similar
difference was seen if CBP was used instead of TNP. However when CK5/6 and/or EGFR
expressing tumors were analyzed without consideration of ER/PR status, the reduction in survival
increased with time, becoming more pronounced at 10 years than at 3 years.
Conclusion: Our findings suggests that CK5/6 and/or EGFR expressing tumor types have a
persistently poorer prognosis over the longer term, an observation that may have important
therapeutic implications as drugs that target the EGFR are currently being evaluated in breast
cancer.
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Gene expression studies using DNA microarrays have
identified several distinct breast cancer subtypes which
differ significantly in prognosis [1,2]. These subtypes
include three main subtypes of estrogen receptor (ER)
negative tumors – the basal-like (ER-/HER2-), the ER-/
HER2+ subtype and the normal-like/unclassified subtype,
and at least 2 types of ER+ tumors (luminal A and luminal
B) [2]. Basal-like tumors typically show high expression of
genes characteristic of the basal epithelial cells of the nor-
mal mammary gland, including stratified epithelial cytok-
eratins, such as cytokeratins 5, 14, 15 and 17 [3]. Basal-
like breast cancers account for around 15% of all invasive
ductal breast cancers of no special type [4] with a higher
prevalence among African-American women [5]. Conven-
tional histopathological as well as molecular studies of
breast cancers with "basaloid" differentiation have shown
that basal-like tumors are often high grade [6], have areas
of necrosis [7], may have a typical or an atypical medul-
lary phenotype [8] and have a distinct pattern of genetic
alterations [6], including frequent TP53 mutations [2]. A
high proportion of BRCA1 tumors exhibit the basal-like
phenotype and germ-line BRCA1 mutations result in
breast cancers that are more likely to be basal-like in
nature [9-12].
The breast cancer subtypes have been extensively charac-
terized by gene expression analysis using DNA microar-
rays and while this remains the gold-standard, it is not
currently feasible for large-scale clinical applications or
retrospective studies using formalin fixed, paraffin-
embedded samples. In these situations the immunohisto-
chemical staining profile (IHC) can be a useful surrogate
of gene expression analysis. However the optimum
immunohistochemical profile of basal-like breast cancer
remains unclear. The "triple negative phenotype", TNP
(ER-, PR-, HER-) is increasingly used as a surrogate marker
for basal-like breast cancer as it has the advantage that
these three stains are already used routinely in clinical
work-up of breast cancers [13]. Although most basal-like
tumors do not express ER, PR, and HER2, some may, and
the overlap between basal-like and TNP breast cancer is
not complete [14]. Moreover, the ER-, HER2-, CK5/6+
and/or EGFR+ profile seems to correlate better with basal-
like breast cancer gene expression profiles [3,15]. We
sought to clarify how the utilization of different marker
combinations affects prognostic outcome.
We have previously shown that tumors expressing the
CK5/6 marker are associated with germline BRCA1 muta-
tions based on data on unselected breast cancer cases from
a single institution (Jewish General Hospital, JGH) [9].
Here we present data on both the JGH series (n = 192) and
a second series of 264 breast cancer cases from the Van-
couver General Hospital (VGH), focusing specifically cor-
relations between IHC profiles and outcome in basal-like
cancer.
Methods
Clinicopathological Review and IHC
For the JGH series, the study design is an ethnically
restricted single hospital-based retrospective cohort study,
as described previously [9]. Of 309 consecutive cases of
Ashkenazi Jewish women age 65 or less diagnosed with a
first primary, non-metastatic, invasive breast cancer
between January 1, 1980 and November 1, 1995 at the Sir
Mortimer B. Davis-Jewish General Hospital, Montreal,
QC, 17 (5.5%) were excluded (because (a) we were una-
ble to locate pathology blocks or (b) we found only carci-
noma in situ was present on the available path blocks,
leaving 292 cases. 192 cases had sufficient material to gen-
erate a tissue microarray. Blocks were identified from each
of these women, and clinicopathological and follow-up
information were obtained by chart review. All of the
specimens were reviewed by one pathologist (L. R. B.) for
histological type, nuclear/histological grade, and lymph
node status, and were stained for ER, PR and HER2 and
CK5/6 IHC, as described previously [9]. The VGH study
group comprised women with primary invasive breast
cancer who underwent surgery for breast cancer between
1974 and 1995 at Vancouver General Hospital. These
were consecutive cases, and the presence of invasive breast
carcinoma was the only selection criterion in this study.
Outcome data were available for all of the patients, with
median follow-up of 15.4 years (range, 6.3–26.6 years)
and the assembly of archival tumor blocks into tissue
microarrays, IHC and scoring were as described previously
[16]. Epidermal growth factor receptor (EGFR) immunos-
tains were also applied to both series, using methods
described previously [15]. Information on the adjuvant
use of hormone therapy or chemotherapy was obtained
from the clinical record; these data were available on 440
cases and 448 cases respectively out of the total of 456
cases in the combined series. All cases had been collected
as part of studies which were subject to ethical approval
obtained from the local institutional ethical review
boards. (McGill University/Jewish General Hospital and
Vancouver General Hospital).
Statistical Analysis
Clinical, pathological, and molecular data were collected
in a mutually blinded fashion. Patient characteristics were
compared using nonparametric Wilcoxon's test and
Fisher's exact test. Borderline statistical significance was
defined as P-values between .05 and .10. Survival rates
were calculated from the date of primary surgery until
death from breast cancer (breast cancer-specific survival).
The median follow-up of those who did not die of breast
cancer was 11.13 years (n = 330; overall follow-up was
8.84 years, n = 456). Ten-year survival curves were esti-Page 2 of 11
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was assessed with the log-rank test.
To estimate the relative risk (RR) of death from breast can-
cer, three Cox proportional hazards models were built, all
of which included the following measured prognostic fac-
tors: Center, age of diagnosis, tumor size, axillary lymph
node status and histological grade. The first model was
built to assess the importance of TNP and included terms
for TNP and [CK5/6 and/or EGFR] positive status. The sec-
ond model was built to assess the importance of CBP and
included terms for CBP and PR positive status. The third
model was built to assess the importance of each compo-
nent of the TNP and CBP criteria and included terms for
ER and HER2 negative status, PR and [CK5/6 and/or
EGFR] positive status. In all three models missing values
were factored in by creating a dichotomized variable (X,
IX) to identify whether or not the variable of interest was
missing using the following method: X = 1 if positive, X =
0 otherwise, IX = 1, if missing, IX = 0 otherwise. Thus a
subject with missing values was (X, IX) = (0, 1), a positive
marker was (X, IX) = (1, 0) and a negative marker was (X,
IX) = (0, 0). This allowed us to include all 456 subjects
(compared to 327 subjects without adjustment for miss-
ing).
The survival model was reanalyzed separately for 244
node-negative and 162 node-positive subjects. Survival
data were analyzed and censored at both 3 years time and
at 10 years time, and significance was assessed at the 5%
level using two-sided tests. All three parsimonious models
were built using the log-likelihood ratio test, employing a
backward approach in which variables with the highest
contribution to the likelihood function were kept in the
model and where the parsimonious model was assumed
when all P-values were below a 10% threshold. The parsi-
monious model is thus built by removing the variables
with the least amount of influence to the likelihood func-
tion; depending on the correlations between each covari-
ate, some will be kept while others will lose statistical
significance and be removed. All three models start by
including the same covariate, that is, center, age of diagno-
sis, tumor size, axillary lymph node status and histologi-
cal grade. Model 1 also includes the variable TNP and
{CK5/6 or EGFR}. Model 2 also includes the variable CBP
and PR. Model 3 also includes the variable ER, HER2, PR
and {CK56 or EGFR}.
As there was an upper age limit in the JGH series and no
upper age limit for the VGH series, the analyses were
repeated without the VGH cases over 65 years. Since the
final results did not essentially differ with and without
older cases, all subjects were kept in the statistical analysis.
Similar models were used to determine the influence of
adjuvant chemotherapy or hormonal therapy on progno-
sis.
A Poisson regression model was built to examine the rela-
tionship between the number of positive lymph nodes
and tumor size in TNP+ and TNP- cases: ln(μ) = ln(Nexam)
+ α + αTNP+ + β*Tsize + βTNP+ *Tsize where: μ = average
number of positive nodes, α = overall intercept, αTNP+ =
extra intercept for TNP+ patients, β = overall slope, βTNP+
= extra slope for TNP+ patients, and the natural logarithm
of the number of nodes examined was used as an offset.
Results
At 10 years time, there was no overall difference in sur-
vival for all breast cancer types between the JGH and VGH
centers (p = .17) and TNP tumors made up 14% of cases
in both series (JGH, 27 tumors, VGH, 36 tumors). In the
combined series, the median age at diagnosis was 9.4
years younger in the TNP group (p = .0006) and the
median length of follow up in survivors was 6.75 years in
the TNP groups versus 9.09 years in the non-TNP group, p
= .02. Exclusion of subjects who did not die of breast can-
cer and were lost to follow up before 10 years did not alter
the statistical significance of the study results. There was a
significant overlap between the TNP and CBP groups with
49/58 (84%) of TNP cases also falling in the CBP group.
Comparison of clinical features in TNP and non-TNP
cases in the combined series (Table 1) showed that TNP
cases had an increased likelihood of a higher histological
grade (odds ratio (OR), for grade 3: 17.7 [95% confidence
interval, C.I., 6.05–51.5], p < .0001), a larger tumor (OR
for tumor >2 cm: 1.85 [95% C.I. 1.04–3.32], p = .04) but
had a decreased likelihood of positive lymph nodes (OR
= 0.44 [95% C.I. 0.23–0.84], p = .01). While there was a
clear correlation between tumor size and the mean
number of positive lymph nodes in both the non-TNP
and the TNP group, this correlation was less strong with
the TNP group (P = 0.01) and the interaction between
tumor size and TNP status on lymph node status was of
borderline significance (p = 0.10, Figure 1). Breast cancer
survival at 3 and 10 years correlated closely with histolog-
ical grade, size and lymph node involvement (Table 2).
The effect of TNP on prognosis was stronger at 3 years
than at 10 years, with TNP conferring a univariate RR of
4.06 [95% C.I. 2.11–7.82], p = .0001 at 3 years (Table 3)
compared to 1.71 [95% C.I. 1.05–2.78], p = .03 at 10
years (Table 4). Although there is a degree of overlap
between the confidence intervals at 3 years and at 10
years, this is small and the fact that the TNP parameter is
not present in parsimonious model 1 at 10 years (Table 4)
but is present in the same model at 3 years provides fur-
ther evidence indicating that the differences are real. A
similar pattern was seen with the CBP variable. Predicta-
bly, TNP cases were less likely to receive hormone therapy
and more likely to receive chemotherapy (Table 1). At 10Page 3 of 11
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therapy versus 66% in the no treatment group; the corre-
sponding figures for CBP were 68% and 62%. These
differences were not significant and there was also no dif-
ference in survival with adjuvant hormone therapy.
In the combined JGH/VGH series, the difference in sur-
vival between the TNP and non-TNP groups (Figure 2)
was most marked at 3 years with an absolute reduction of
16.7% in the TNP group (76.8% versus 93.5%, p < .0001).
Although the absolute reduction in survival of 9.2% at 10
years in the TNP group was still significant (p = .03), the
difference appeared to be reducing with time, suggesting
that long term survivors in the TNP group may have a
comparable survival to non-TNP cases. When using CBP
instead of TNP a similar overall survival pattern emerged
with a significant difference at 3 years (77.4% versus
93.4%, p =< .0001) that also became less marked at 10
years.
However, when tumors negative for CK5/6 and EGFR
expression were compared to tumors that expressed either
CK5/6 or EGFR (Figure 3) the absolute survival difference
was notably greater at 10 years (17.1%, p = .0007), than
that at 3 years (7.8%, p = .02). This was reflected in the
multivariate parsimonious models (Table 3 and 4) which
showed that at 3 years time, both TNP and CBP parame-
ters not only remained in their respective parsimonious
models but both also worked well in predicting outcome
(models 1 and 2). As both models share ER negative and
HER2 negative status, these appear to be the main driving
factors predicting early outcome. Indeed, when all com-
ponents of TNP and CBP are analyzed separately (model
3), only ER negative and HER2 negative status remained
in the parsimonious model while positive PR status and
[CK5/6+ and/or EGFR+] status fell out of the model.
In contrast, the data at 10 years indicates that ER negative
and HER negative status diminishes in influence with
increasing time, with [CK5/6+ and/or EGFR+] status
becoming the main driving factor. Therefore CBP (which
incorporates CK5/6 and/or EGFR+) may be a better model
at 10 years.
Discussion
The data presented here show that different immunohis-
tochemical marker combinations may influence progno-
sis at different points in time. This is in agreement with the
recent findings of Anderson et al. who using the SEER
database found that at 17 months, ER- hazard rates
peaked at 7.5% per year then declined, whereas ER+ haz-
ard rates were comparatively constant at 1.5–2% per year;
falling ER- and constant ER+ hazard rates crossed at 7
years after which time prognosis was better for ER+ cases
[17].
TNP had a marginally greater effect on prognosis in lymph
node negative patients compared to lymph node positive
patients (Figures 4 and 5). The univariate relative risk for
breast cancer death at 3 years in the TNP group versus the
Table 1: Age at diagnosis, tumor characteristics and treatment given in the TNP and non-TNP groups.
Clinical Feature No. of cases Non-TNP No. of cases TNP Odds Ratio [95% CI] P-value*
Center VGH 228 36
JGH 165 27 1.04 [0.61; 1.77] 0.89
Age at diagnosis 25–49 years 116 32
50–95 years 277 31 0.41 [0.24; 0.70] 0.001
Histological grade Grade 1 120 4
Grade 2 193 15 2.33 [0.76; 7.19] 0.15
Grade 3 68 40 17.65 [6.05; 51.45] <0.0001
Missing 12 4
Tumor size 0–2 cm 161 18
2.01–15 cm 217 45 1.85 [1.04; 3.32] 0.04
Missing 15 0
Lymph node status Negative 205 41
Positive 149 13 0.44 [0.23; 0.84] 0.01
Missing 39 9
Hormonal Treatment None 219 49
Yes 161 11 0.31 [0.15; 0.61] 0.0003
Missing 13 3
Chemotherapy None 279 35
Yes 108 26 1.92 [1.10; 3.34) 0.02
Missing 6 2
* P-values based on Fisher's exact test.Page 4 of 11
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negative patients and lymph node positive patients
respectively, giving a magnitude of reduction in survival at
3 years of 0.68 in lymph node positive patients compared
to lymph node negative patients. Whether lymph node
status has less prognostic value in basal-like breast cancers
remains a contentious issue. For example in their recent
study of African-American women, Carey et al did not see
a poor survival in lymph node negative basal-like breast
cancer, but it was very poor in lymph node positive cases
[5] while other groups have found that node-negative
basal-like breast cancer also carries a poor prognosis [18].
In this study the limited correlation between tumor size
and mean number of lymph nodes in the TNP group and
the modest difference of the effect of TNP between lymph
node negative and lymph node positive groups suggest
that lymph node involvement is a less reliable predictor of
prognosis in the TNP group.
Data from the first cohort studied (JGH) indicate that
breast cancers with the TNP have a worse prognosis at
least in the first three years after diagnosis but this differ-
ence in prognosis may diminish with time from diagno-
sis. These data were validated in a second large
Table 3: Cox proportional model for survival until death from breast cancer at 3 years.
Univariate Full Multivariate Parsimonious
Model Variable RR (95% CI) P RR (95% CI) P RR (95% CI) P
Model 1 CK5/6+ and/or EGFR+ No 1. 1.
Yes 2.24 [1.14; 4.39] 0.02 1.20 [0.50; 2.85] 0.68 not present
TNP No 1. 1. 1.
Yes 4.06 [2.11; 7.82] 0.0001 3.42 [1.37; 8.49] 0.008 4.40 [2.23; 8.69] 0.0001
Model 2 PR No 1. 1.
Yes 0.43 [0.23; 0.81] 0.009 0.70 [0.34; 1.45] 0.34 not present
CBP No 1. 1. 1.
Yes 3.73 [1.88; 7.39] 0.0002 3.13 [1.26; 7.77] 0.01 4.29 [2.12; 8.68] 0.0001
Model 3 ER- HER2- No 1. 1. 1.
Yes 4.39 [2.34; 8.23] 0.0001 4.82 [1.95; 11.9] 0.0006 5.38 [2.77; 10.5] 0.0001
PR No 1. 1.
Yes 0.43 [0.23; 0.81] 0.009 0.82 [0.38; 1.76] 0.61 not present
CK5/6+ and/or EGFR+ No 1. 1.
Yes 2.24 [1.14; 4.39] 0.02 0.99 [0.42; 2.34] 0.98 not present
All statistical modeling adjust for variables with missing values (see methods). The full multivariate model also includes terms for centre, age of 
diagnosis, histological grade, tumor size and lymph node. Parsimonious model was assumed when all P-values were below 10%. All three 
parsimonious models also included terms for tumor size and lymph node status. Parsimonious model-2 also included a term for Histological grade 
while parsimonious model-3 also included a term for the centre. The total number of subjects is 456. The total number of events is 39 at 3 years.
Table 2: Univariate Cox proportional hazards model for survival until death from breast cancer at 3 years and 10 years.
3 years 10 years
Variable Definition RR (95% CI) P RR (95% CI) P
Center VGH 1. 1.
JGH 0.67 [0.35; 1.31] .25 0.76 [0.51; 1.13] .17
Age of diagnosis < 50 years 1. 1.
≥ 50 years 1.10 [0.55; 2.16] .79 0.97 [0.66; 1.44] .89
Histological grade*, § 1 1. 1.
2 2.62 [0.88; 7.80] .08 1.63 [0.97; 2.73] .06
3 5.47 [1.84; 16.2] .002 2.37 [1.36; 4.11] .002
Tumor Size§ < 2 cm 1. 1.
≥ 2 cm 3.22 [1.42; 7.32] .005 2.82 [1.78; 4.46] .0001
Lymph nodes§ No 1. 1.
Yes 2.78 [1.37; 5.65] .005 2.21 [1.46; 3.32] .0002
* Test of overall histological grade. P-value = 0.004 (at 3 years) and 0.009 (at 10 years).
§ Adjusting for missing values.
The total number of subjects is 456. The total number of events is 39 at 3 years and 111 at 10 years.Page 5 of 11
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Poisson regression curve examining the relationship between tumor size, lymph node status and TNP groupFigure 1
Poisson regression curve examining the relationship between tumor size, lymph node status and TNP group. 
The number of positive lymph nodes showed a closer correlation with tumor size in the non-TNP group compared to the TNP 
group.
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Table 4: Cox proportional model for survival until death from breast cancer at 10 years time.
Univariate Full Multivariate Parsimonious
Model Variable RR (95% CI) P RR (95% CI) P RR (95% CI) P
Model 1 CK5/6+ and/or EGFR+ No 1. 1. 1.
Yes 2.00 [1.33; 3.02] 0.0009 1.95 [1.18; 3.21] 0.009 1.92 [1.27; 2.89] 0.002
TNP No 1. 1.
Yes 1.71 [1.05; 2.78] 0.03 0.96 [0.51; 1.79] 0.89 not present
Model 2 PR No 1. 1. 1.
Yes 0.59 [0.40; 0.85] 0.005 0.64 [0.42; 0.98] 0.04 0.62 [0.42; 0.92] 0.02
CBP No 1. 1.
Yes 1.72 [1.06; 2.80] 0.03 1.18 [0.64; 2.17] 0.60 not present
Model 3 ER- HER2- No 1. 1. 1.
Yes 1.96 [1.30; 2.97] 0.002 1.41 [0.80; 2.49] 0.24 1.64 [0.99; 2.70] 0.05
PR No 1. 1.
Yes 0.59 [0.40; 0.85] 0.005 0.77 [0.49; 1.20] 0.24 not present
CK5/6+ and/or EGFR+ No 1. 1. 1.
Yes 2.00 [1.33; 3.02] 0.0009 1.54 [0.92; 2.58] 0.10 1.69 [1.04; 2.74] 0.03
All statistical modeling adjust for variables with missing values (see methods). The full multivariate model also includes terms for centre, age of 
diagnosis, histological grade, tumor size and lymph node. Parsimonious model was assumed when all P-values were below 10%. All three 
parsimonious models also included terms for tumor size and lymph node status. Parsimonious model-2 also included a term for Histological grade 
while parsimonious model-3 also included a term for the centre. The total number of subjects is 456. The total number of events is 111 at 10 years.
BMC Cancer 2007, 7:134 http://www.biomedcentral.com/1471-2407/7/134independent data set (VGH). Both data sets showed very
similar overall survival curves suggesting that they are gen-
erally comparable. Although both data sets were identi-
fied retrospectively, this is counterbalanced by the fact
that they originate from different centers and the degree of
consistency between the two data sets which strengthens
the overall findings. However, given the small numbers of
cases analyzed, any impact of treatment on survival strat-
ified by TNP status would have had to be very large to
become apparent and further larger, preferably rand-
omized, studies are required to assess this in greater detail.
The data presented here add to the growing body of evi-
dence that basal-like breast tumors have a worse progno-
sis [13,15,18,19] and respond less well to chemotherapy
at relapse [20], although there remains a significant
degree of heterogeneity within this group [6,21-24]. Some
of these studies have used microarray-based gene expres-
sion studies to identify the basal-like group and, while
these studies are likely to be more accurate in delineating
the basal phenotype than standard immunohistochemi-
cal methods, they are not yet routinely used in clinical
practice. The advantage of this study is that it uses markers
that are readily available in most pathology departments
and is therefore directly translatable into routine clinical
management, and can be applied to archival specimens
for which long-term follow-up information is already
available.
A large number of new markers are emerging which aim
to further delineate the basal phenotype [23,25]. How-
ever, ER, PR, HER2, EGFR and CK5/6 are already routinely
available in most centers. ER, PR, and HER2 in particular
are used to guide treatment decisions in breast cancer [26]
and it is therefore important to know exactly how expres-
sion of these markers affects prognosis. Haffty et al. have
recently published prognosis data on a series of 482
patients, 117 of which had a TNP [13]. The median follow
up time was 7.9 years and TNP was an independent pre-
dictor of disease-specific survival (hazard ratio = 1.79;
95% CI 1.03–3.22). Another recent study showed that in
the neoadjuvant setting, patients with ER negative and
HER2 negative breast cancer have higher sensitivity to
anthracycline-based chemotherapy than the luminal sub-
Survival until breast cancer death by TNP statusFigure 2
Survival until breast cancer death by TNP status. Survival at 3 years time was 76.8% in the TNP cases versus 93.5% 
among non-TNP cases (p < .0001); Survival at 10 years time were, respectively 65.0% and 74.2% (p = .03).
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response [27]. Several new drugs that target the EGFR in
breast cancer are currently being evaluated [28] and the
observations presented here suggest that the effects of
these drugs may become more apparent over the longer
term, beyond the time over which a typical drug trial
would extend. This would have important implications
for trial design and interpretation of results. Finally, an
increasing number of immunohistochemical markers are
being utilized in the identification of basal-like and
BRCA1-related breast cancers [18,29-31], and further val-
idation of these additional markers will be required if they
are also to be used as a guide to clinical prognosis and
therapeutic choices [14].
Conclusion
Our data confirms that TNP is useful as a prognostic
marker, but also suggests that the effect of TNP on survival
reduces over time and that focusing on CK5/6 and/or
EGFR expression may provide a better marker for long
term prognosis (beyond three years).
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Survival until breast cancer death by Ck5/6 and EGFR statusFigure 3
Survival until breast cancer death by Ck5/6 and EGFR status. Survival at 3 years time was 85.6% among CK5/6 and/or 
EGFR positive cases versus 93.4% among cases that were negative for both CK5/6 and EGFR (p = .02); Survival at 10 years time 
was 61.4% and 78.5% (p = .0007) respectively.
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Relationship between TNP, survival and lymph node status – lymph node positive subgroupFigure 4
Relationship between TNP, survival and lymph node status – lymph node positive subgroup. In TNP cases, the 
magnitude of the decrease in survival was approximately 1.5-fold greater at 3 years in the lymph node positive subgroup (Fig-
ure 4) compared to the lymph node negative subgroup (Figure 5).
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